Zura Bio Ltd (ZURA) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-23

Key Insights

CFO Eric Hyllengren was separated from the company on April 20, 2026, with the filing explicitly stating this was unrelated to financial results, operations, or accounting disagreements, suggesting an amicable transition.
Marlyn Mathew was promoted from Vice President of Finance and Accounting to Principal Financial Officer and Principal Accounting Officer with an increased annual base salary to $366,415, indicating internal succession planning and continuity.
Ms. Mathew brings relevant accounting experience from her controller role at Immunovant (2019-2022) and has been with Zura Bio since June 2022, providing stability and institutional knowledge in the finance function.
The separation agreement provides Hyllengren with three months of base salary and up to six months of COBRA premium reimbursement, structured contingently on compliance, representing standard severance for a CFO-level departure.

Want the newest filings?

This analysis covers the filing from 2026-04-23. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-19

Zura Bio Ltd announced its 2025 full fiscal year financial results, providing investors with an update on the company's performance and progress.
The company filed its updated corporate presentation, which may be used in upcoming presentations at conferences and investor meetings, giving investors insight into the company's strategy and developments.
As an emerging growth company, Zura Bio Ltd has elected not to use the extended transition period for complying with new or revised financial accounting standards, potentially indicating a focus on transparency and compliance.

Filed: 2026-01-26

The CEO, Robert Lisicki, has resigned effective January 21, 2026, and the company has appointed Sandeep Kulkarni, a current director, as the new CEO.
The company has entered into a separation agreement with Lisicki, which includes transition compensation, severance, and extended stock option exercise periods.
Kulkarni has been granted a new-hire option award and a performance-based option award as part of his compensation package as the new CEO.

Filed: 2026-01-12

Zura Bio Limited provided an updated corporate presentation that may be used for upcoming presentations and investor meetings, indicating the company's continued engagement with the investment community.
The company issued a press release announcing corporate and clinical trial updates, including updates on its cash runway and expected topline data readout timelines for its two ongoing Phase 2 clinical studies of its lead drug candidate, tibulizumab.
Zura Bio Limited is an emerging growth company, which may indicate opportunities for investors but also potential risks and challenges associated with a less-established business.

Other reports for Zura Bio Ltd

Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.